Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15624381 | 0.97 | CCR1 (0.46) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL12446429 | 0.85 | CYP3A4 (0.40) | CCR1CCR8 | |
| SCHEMBL31645573 | 0.83 | KDM4E (0.71) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL12446471 | 0.83 | KDM4E (0.71) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL116643 | 0.83 | — | — | |
| SCHEMBL4651412 | 0.82 | MEN1 (0.68) | KDM4EL3MBTL1LMNAHSP90AA1SMN1; SMN2 | |
| SCHEMBL19806300 | 0.80 | PIM1 (0.34) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL12446775 | 0.80 | RAB9A (0.50) | KDM4ETDP1LMNATP53ALOX15 | |
| SCHEMBL7009235 | 0.80 | ALDH1A1 (0.46) | KDM4EMEN1KMT2ARAB9AMAPT | |
| SCHEMBL22289928 | 0.78 | MAPT (0.54) | KDM4ELMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | COLGATE UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| WO-2023191953-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2014044685-A1 | FLUORINATED COBALT REDOX MEDIATOR, METHOD FOR PRODUCING THE SAME, AND ITS USE IN DYE-SENSITIZED SOLAR CELL | SOLVAY SA (BE) | 2014-03-27 | — | — | WO | disclosed |
| EP-2711360-A1 | Fluorinated cobalt redox mediator, method for producing the same, and its use in dye-sensitized solar cell | Solvay SA (BE) | 2014-03-26 | — | — | EP | disclosed |
| US-20110309304-A1 | LUMINESCENT SILVER COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110309304-A1 | LUMINESCENT SILVER COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110309304-A1 | LUMINESCENT SILVER COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2011152358-A1 | MEMBRANE CONTAINING SILVER COMPLEX | 住友化学株式会社 (JP) | 2011-12-08 | — | — | WO | disclosed |
| EP-2360162-A1 | LUMINESCENT SILVER COMPLEXES | Sumitomo Chemical Company, Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360162-A1 | LUMINESCENT SILVER COMPLEXES | Sumitomo Chemical Company, Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564636-B2 | Pnictogen-containing heterocyclic compounds and their use | CBR1, PNPO, NOX3 | CCR1 851/4885CCR8 2224/4885KDM4E 3857/4885 |
| US-20240285772-A1 | PNICTOGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE | PYGL, UGT2B7, CYP2E1 | CCR1 1806/4885CCR8 1780/4885KDM4E 3153/4885 |
| US-20110309304-A1 | LUMINESCENT SILVER COMPLEX | SOD1, AS3MT, GLO1 | CCR1 4833/4885CCR8 4736/4885KDM4E 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.